120 related articles for article (PubMed ID: 3079085)
41. Cessation of steroids in renal allograft recipients on combined cyclosporine A, azathioprine, and prednisolone.
O'Connell P; d'Apice A; Walker R; Francis D; Kincaid-Smith P
Transplant Proc; 1988 Feb; 20(1):11-3. PubMed ID: 3278450
[No Abstract] [Full Text] [Related]
42. Cyclosporine levels together with metabolites are more effective than cyclosporine parent compound levels alone in predicting hepatic toxicity after liver transplantation.
Avolio AW; Agnes S; Nanni G; Citterio F; Magalini SC; Castagneto M
Transplant Proc; 1991 Aug; 23(4):2221-2. PubMed ID: 1871853
[No Abstract] [Full Text] [Related]
43. Decreased rate of growth of hepatocellular carcinoma recurrence after liver transplantation in patients maintained on cyclosporine immunosuppression.
O'Grady JG; Johnson PJ; Zaman S; Calne RY; Williams R
Transplant Proc; 1988 Jun; 20(3 Suppl 3):394-6. PubMed ID: 2838941
[No Abstract] [Full Text] [Related]
44. Overcoming early cyclosporine nephrotoxicity after liver transplantation.
Burdick JF; Colombani PM; Pitt HA; Perler BA; Merritt WT; Crandall BC; Mitchell MC; Herlong HF; Williams GM
Transplant Proc; 1989 Feb; 21(1 Pt 2):2236-7. PubMed ID: 2652724
[No Abstract] [Full Text] [Related]
45. FK 506 rescue therapy: early conversion improves efficacy.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
[No Abstract] [Full Text] [Related]
46. Immunosuppression with cyclosporine, azathioprine, and prednisolone in cadaver renal allograft recipients.
Jones RM; Murie JA; Allen R; Jaskowski A; Morris PJ
Transplant Proc; 1987 Feb; 19(1 Pt 3):1926. PubMed ID: 3274453
[No Abstract] [Full Text] [Related]
47. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group.
Porayko MK; Gonwa TA; Klintmalm GB; Wiesner RH
Transplant Proc; 1995 Feb; 27(1):1114-6. PubMed ID: 7533358
[No Abstract] [Full Text] [Related]
48. Kidney impairment in long-term survivors following cardiac transplantation.
Wahlers T; Fieguth HG; Cremer J; Albes J; Heublein B; Schäfers HJ; Haverich A; Borst HG
Transplant Proc; 1990 Aug; 22(4):1449. PubMed ID: 2389358
[No Abstract] [Full Text] [Related]
49. Allogeneic intrasplenic hepatocyte transplantation in the Gunn rat using cyclosporine A immunosuppression.
Cobourn CS; Makowka L; Falk JA; Falk RE
Transplant Proc; 1987 Feb; 19(1 Pt 2):1002-3. PubMed ID: 3274263
[No Abstract] [Full Text] [Related]
50. Favourable clinical results of Sandimmun-Neoral in malabsorbing liver and heart transplant recipients.
Färber L; Maibücher A; Geissler F; Gutzler F; Wiesinger FO; Winkler M
Transplant Proc; 1994 Oct; 26(5):2988-93. PubMed ID: 7940944
[No Abstract] [Full Text] [Related]
51. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
[No Abstract] [Full Text] [Related]
52. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H
Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
[No Abstract] [Full Text] [Related]
53. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Wahlstrom HE; Sanchez-Urdazpal L; Richards T; Crotty P; Beaver S
Transplant Proc; 1993 Feb; 25(1 Pt 1):665-8. PubMed ID: 7679835
[No Abstract] [Full Text] [Related]
54. Cyclosporine in transplantation of the liver in the dog.
Williams JW; Peters TG; Haggitt R; Van Voorst S
Surg Gynecol Obstet; 1983 Jun; 156(6):767-73. PubMed ID: 6344281
[TBL] [Abstract][Full Text] [Related]
55. Hypertension after renal transplantation. A comparison of cyclosporine and conventional immunosuppression.
Chapman JR; Marcen R; Arias M; Raine AE; Dunnill MS; Morris PJ
Transplantation; 1987 Jun; 43(6):860-4. PubMed ID: 3296353
[TBL] [Abstract][Full Text] [Related]
56. Comparative effects of immunosuppressive therapy on glucose metabolism.
Smith WG; Thomas S; Griffin PJ; Salaman JR
Transplant Proc; 1989 Feb; 21(1 Pt 2):1502-3. PubMed ID: 2652484
[No Abstract] [Full Text] [Related]
57. Optimal clinical regimens for living related liver transplantation.
Malagó M; Rogiers X; Wadström J; Burdelski M; Broelsch CE
Transplant Proc; 1994 Oct; 26(5):2665-8. PubMed ID: 7940834
[No Abstract] [Full Text] [Related]
58. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular effects of cyclosporine in heart transplant recipients.
Scott JP; Higenbottam TW; Hutter JA; Smyth RL; Glandville C; Wallwork J
Transplant Proc; 1990 Aug; 22(4):1740-1. PubMed ID: 2389447
[No Abstract] [Full Text] [Related]
60. Analysis of biliary complications following orthotopic liver transplantation.
Ringe B; Oldhafer K; Bunzendahl H; Bechstein WO; Kotzerke J; Pichlmayr R
Transplant Proc; 1989 Feb; 21(1 Pt 2):2472-6. PubMed ID: 2652810
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
